## Abstract Hydrogels of poly(methacrylic acid‐__co__‐__N__‐vinyl pyrrolidone) were synthesized and evaluated for their use as carriers for oral protein delivery. Insulin loading efficiencies were determined to be near 90% for carriers crosslinked with ethylene glycol dimethacrylate with correspond
Engineering temperature-sensitive poly(N-isopropylacrylamide) polymers as carriers of therapeutic proteins
✍ Scribed by Hasan Uludag; Bryan Norrie; Niki Kousinioris; Tiejun Gao
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 428 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0006-3592
- DOI
- 10.1002/bit.1086
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
This study was carried out to engineer N‐isopropylacrylamide (NiPAM) polymers that contain protein‐reactive N‐acryloxysuccinimide (NASI) and hydrophobic alkylmethacrylates (AMAs). These thermoreversible, protein‐conjugating polymers hold potential for retention of therapeutic proteins at an application site where tissue regeneration is desired. The lower critical solution temperatures (LCST) of the polymers were effectively controlled by the AMA mole content. The AMAs with longer side‐chains were more effective in lowering the LCST. Polymers without NASI exhibited a stable LCST in phosphate buffer and in serum over a 10‐day study period. The LCST of polymers containing NASI was found to increase over time in phosphate buffer, but not in serum‐containing medium. The LCST increase in phosphate buffer was proportional to the AMA content. The feasibility of localizing a therapeutic protein, recombinant human bone morphogenetic protein‐2 (rhBMP‐2), to a site of application was explored in a rat intramuscular injection model. The results indicated that polymers capable of conjugating to rhBMP‐2 were most effective in localizing the protein irrespective of the LCST (13–25°C). For polymers with no NASI groups, a lower LCST resulted in a better rhBMP‐2 localization. We conclude that thermosensitive polymers can be engineered for delivery of therapeutic proteins to improve their therapeutic efficacy. © 2001 John Wiley & Sons, Inc. Biotechnol Bioeng 73: 510–521, 2001.
📜 SIMILAR VOLUMES